Zhou, Xiao-Dong and Targher, Giovanni and Byrne, Christopher D. and Somers, Virend and Kim, Seung Up and Chahal, C. Anwar A. and Wong, Vincent Wai-Sun and Cai, Jingjing and Shapiro, Michael D. and Eslam, Mohammed and Steg, Philippe Gabriel and Sung, Ki-Chul and Misra, Anoop and Li, Jian-Jun and Brotons, Carlos and Huang, Yuli and Papatheodoridis, George V. and Sun, Aijun and Yilmaz, Yusuf and Chan, Wah Kheong and Huang, Hui and Mendez-Sanchez, Nahum and Alqahtani, Saleh A. and Cortez-Pinto, Helena and Lip, Gregory Y. H. and de Knegt, Robert J. and Ocama, Ponsiano and Romero-Gomez, Manuel and Fudim, Marat and Sebastiani, Giada and Son, Jang Won and Ryan, John D. and Ikonomidis, Ignatios and Treeprasertsuk, Sombat and Pastori, Daniele and Lupsor-Platon, Monica and Tilg, Herbert and Ghazinyan, Hasmik and Boursier, Jerome and Hamaguchi, Masahide and Nguyen, Mindie H. and Fan, Jian-Gao and Goh, George Boon-Bee and Al Mahtab, Mamun and Hamid, Saeed and Perera, Nilanka and George, Jacob and Zheng, Ming-Hua (2023) An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatology International, 17 (4). pp. 773-791. ISSN 1936-0533, DOI https://doi.org/10.1007/s12072-023-10543-8.
Full text not available from this repository.Abstract
Background Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of similar to 25-30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been proposed for this condition. MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in the literature on fatty liver disease, the CVD risk associated with MAFLD is often underestimated, especially among Cardiologists. Methods and results A multidisciplinary panel of fifty-two international experts comprising Hepatologists, Endocrinologists, Diabetologists, Cardiologists and Family Physicians from six continents (Asia, Europe, North America, South America, Africa and Oceania) participated in a formal Delphi survey and developed consensus statements on the association between MAFLD and the risk of CVD. Statements were developed on different aspects of CVD risk, ranging from epidemiology to mechanisms, screening, and management. Conculsions The expert panel identified important clinical associations between MAFLD and the risk of CVD that could serve to increase awareness of the adverse metabolic and cardiovascular outcomes of MAFLD. Finally, the expert panel also suggests potential areas for future research.
| Item Type: | Article |
|---|---|
| Funders: | None |
| Uncontrolled Keywords: | Metabolic (dysfunction)-associated fatty liver disease; MAFLD; Non-alcoholic fatty liver disease; Cardiovascular disease; Consensus; Delphi survey |
| Subjects: | R Medicine > RA Public aspects of medicine R Medicine > RB Pathology |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 06 Oct 2025 13:28 |
| Last Modified: | 06 Oct 2025 13:28 |
| URI: | http://eprints.um.edu.my/id/eprint/48278 |
Actions (login required)
 |
View Item |
